(previous POV, motion sickness or family history of POV)No predispositionPredisposition presentNADuration of anesthesia >45 minNoYesNAHigh-risk surgery(tonsillectomy, tympanoplastystrabismus)Not high PONV risk proceduresHigh PONV risk (tonsillectomy, tympanoplastystrabismus)NAMultiple doses of opioidsNoYesNA NA, not…
On a case-by-case decision: further interventionsInterventions for treatment1. Drug B2. Drug C (in case of ineffectiveness of treatment in stage 1) (i.e., Drug B)1. Drug C2. Drug D (in case…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 14 Postoperative nausea and vomiting management: cost-effectiveness and patient outcome Paul S. Myles Postoperative nausea and vomiting (PONV) and postdischarge nausea and vomiting (PDNV) are…
Figure 13.1 Percentage of patients who experienced nausea and/or vomiting (a) in the postanesthesia care unit and (b) postdischarge. The incidence of severe vomiting in the postanesthesia care unit was…
Figure 9.1 Simulated plasma concentrations of propofol during the first 6 h postoperatively. Propofol administered as an induction agent (PI); propofol administered for induction and at the end of surgery…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 6 Pharmacology of serotonin antagonists Jacob Nouriel and Gildasio De Oliveira Serotonin antagonists were the first group of drugs specifically developed to prevent and/or treat…
12.5–25 mg IMPerphenazine2–4 mg PO2.5–5 mg IMc; 1 mg IVcProchlorperazine5–10 mg IM, IVButyrophenonesDroperidol0.625–1.25 mg IVHaloperidol0.5–2 mg IM, IVBenzamidesMetoclopramide10–20 mg IM, IVAnticholinergicsTransdermal scopolamine1.5 mg transdermal IM, intramuscular; IV, intravenous; PO, oral….
SNP in HTR3B: rs1176744, rs1672717, rs3782025, rs3758987, Tyr129Ser, Ala223Thr, Y129S; -100_-102delAAG deletion, c5+201_+202delCA, c6-137C>TSNP in HTR3C: K163 N, A405GSNP in HTR3D: rs6443930Cytochrome P450 2D6 isoformCYP2D6SNP: rs16947 (CYP2D6*2), rs35742686 (CYP2D6*3A), rs1135824…
Figure 7.1 Schematic drawing of our three body fluid compartments. The sizes of these body fluid volumes have been measured under steady state conditions by the use of tracer methods….
Figure 22.1 Two-dimensional glycocalyx–cleft model of capillary fluid exchange: the sub-glycocalyx space is protected and is protein free, forming the basis for the “no-reabsorption rule.” The glycocalyx–cleft model identifies glycocalyx…
